ABL1 and cancer: Drug-drug interaction accounts for about 20-30% of all adverse reactions to drugs and are particularly important in the treatment and management of cancer patients to optimize dosing and manage toxicity associated with the cancer treatment.[1] Imatinib, is a rationally designed potent inhibitor of several protein kinases including BCR-ABL and cKIT.